All News
Half the Experts are Wrong (2.17.2023)
Dr. Jack Cush reviews the news and tries to stump the expert panel this week on the podcast.
Read Article
Join us on 3/18 and 3/19 in Dallas, Texas, or virtually for RheumNow Live! Will we see you there?
https://t.co/Pv5hywp0ZQ https://t.co/lux83rqNfz
Links:
Dr. John Cush RheumNow ( View Tweet)
Does Methotrexate Increase Skin Cancer Risk?
A report from the British Journal of Cancer has also shown an increased risk of basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) with MTX use; and more so with higher doses.
https://t.co/8AkdkrZs44 https://t.co/ZXrqlbZiZV
Links:
Dr. John Cush RheumNow ( View Tweet)
Deucravacitinib - Effective in Systemic Lupus Erythematosus
A Phase II, multicenter study has demonstrated the efficacy and safety of deucravacitinib, an oral, selective, allosteric inhibitor of TYK2, in adults with active SLE.
https://t.co/YS8n02BEsk https://t.co/4sBd88AhtK
Links:
Dr. John Cush RheumNow ( View Tweet)
Can I stop MTX in RA?
Dr. Janet Pope and Dr. Charis Meng discuss ---should RA Patients with Controlled Disease Taper Methotrexate from Targeted Therapy or Continue It? Risk Differences in Sustaining Remission from a Systematic Review and Meta-analysis.
https://t.co/yMuVVqu0Gf https://t.co/T6PYZ6pJS4
Links:
Dr. John Cush RheumNow ( View Tweet)
Congratulations to Dr Philip Mease, the 2023 recipient of the RWCS "Kahuna" award, for lifetime excellence as a teacher/educator! @RWCSmtg #RWCS23 https://t.co/iXzQsJouu9
Dr. John Cush RheumNow ( View Tweet)
Your #RA patient clearly has active disease that requires new Rx. Is your choice driven by:
Dr. John Cush RheumNow ( View Tweet)
Future therapies for IgG4 re dz. @anisha_dua @RWCSmtg @RheumNow #RWCS23 https://t.co/3pwBiBTf2N
Dr. John Cush RheumNow ( View Tweet)
“Pathology is helpful but not diagnostic” Dr. Dua #RWCS23 @RheumNow here are your features found on biopsy. https://t.co/J9a6S9XY2D
Dr. Rachel Tate uptoTate ( View Tweet)
Dr. Dua reviews IgG4 disease involvement at #RWCS23 @RWCSmtg @RheumNow https://t.co/WHNSxhKGUU
Dr. Rachel Tate uptoTate ( View Tweet)
Steroids assisting options - CTX, LEF or RTX @anisha_dua @RWCSmtg @RheumNow #RWCS23 https://t.co/ENfg650B9A
Dr. John Cush RheumNow ( View Tweet)
IgG4 rel dz, steroid response is dramatic, but you need more than steroids for long term remission. @anisha_dua @RWCSmtg @RheumNow https://t.co/wq129L6DXT
Dr. John Cush RheumNow ( View Tweet)
IgG4 levels are often elevated and helpful, but not always. @anisha_dua @RWCSmtg @RheumNow #RWCS23 https://t.co/CcdPcxYIbl
Dr. John Cush RheumNow ( View Tweet)
IgG4 rel dz pathology. @anisha_dua @RWCSmtg @RheumNow https://t.co/LKIZ1BOejK
Dr. John Cush RheumNow ( View Tweet)
IgG4 related disease (a proliferative, fibrotic dz) manifestations by Dr Aisha Dua at RWCS @anisha_dua #rwcs23 @RWCSmtg @RheumNow https://t.co/hy6ZuOY2Ti
Dr. John Cush RheumNow ( View Tweet)
New Laboratory Insights for the ANA+ Consult
A new study suggests that use of ELISA assays for CXCL-10 and IFN-α can predict which ANA+ individuals may progress to developing a systemic autoimmune rheumatic disease (SARD).
https://t.co/Ub9pUHPRrV https://t.co/5q2yrNLD5e
Links:
Dr. John Cush RheumNow ( View Tweet)
While his talk didn’t focus on treatment, thoughtfulness regarding treatment for pain is important to our patients. Dr. Mease @RWCSmtg @RheumNow #RWCS23 https://t.co/f946SSeRWo
Dr. Rachel Tate uptoTate ( View Tweet)
Dr. Shenoi discusses a new bio markers in sJIA lung disease. #RWCS23 @RheumNow @RWCSmtg https://t.co/Nn3KjmGNfu
Dr. Rachel Tate uptoTate ( View Tweet)
How do you treat sJIA lung disease? Lots of steroids. Lung disease may stabilize but may not resolve. Dr. Shenoi @RWCSmtg #RWCS23 @RheumNow https://t.co/d5HiRy4Ud4
Dr. Rachel Tate uptoTate ( View Tweet)
MIS-c 2023 updated diagnostic criteria broken down by information type. Dr. Shenoi #RWCS23 @RheumNow @RWCSmtg https://t.co/U24sQiEF37
Dr. Rachel Tate uptoTate ( View Tweet)